Search tips
Search criteria 


Logo of dermaendoLink to Publisher's site
Dermatoendocrinol. 2012 April 1; 4(2): 128–136.
PMCID: PMC3427191

Does vitamin D deficiency contribute to erectile dysfunction?


Erectile dysfunction (ED) is a multifactorial disease, and its causes can be neurogenic, psychogenic, hormonal and vascular. ED is often an important indicator of cardiovascular disease (CVD) and a powerful early marker for asymptomatic CVD. Erection is a vascular event, and ED is often a vascular disease caused by endothelial damage and subsequent inhibition of vasodilation. We show here that risk factors associated with a higher CVD risk also associate with a higher ED risk. Such factors include diabetes mellitus, hypertension, arterial calcification and Inflammation in the vascular endothelium. Vitamin D deficiency is one of several dynamics that associates with increased CVD risk, but to our knowledge, it has not been studied as a possible contributor to ED. Here we examine research linking ED and CVD and discuss how vitamin D influences CVD and its classic risk factors—factors that also associate to increased ED risk. We also summarize research indicating that vitamin D associates with reduced risk of several nonvascular contributing factors for ED. We conclude that VDD contributes to ED. This hypothesis should be tested through observational and intervention studies.

Keywords: vitamin D, erectile dysfunction, vascular diseases, peripheral arterial disease, nitric oxide, inflammation, calcification, hypertension, diabetes, vasodilation

Introduction: Important Facts Pertaining to this Discussion

Vitamin D is a steroid hormone produced in human skin by sunlight stimulation, specifically the ultraviolet-B (UVB) portion of the sunlight spectrum; about 80% of vitamin D is thus obtained.1 The angle of sunlight varies greatly by season. In summer, the sun is overhead at noon, but in winter it stays closer to the horizon, and sunlight must pass through more atmosphere, which filters out much or all of the UVB. Therefore, availability of UVB exposure, and its resultant vitamin D production in skin, is highest in late spring through early fall and lowest from late fall through early spring. Consequently, vitamin D levels in the bloodstream also vary by season, with levels highest in late spring through early fall and lowest from late fall through early spring. For example, vitamin D levels in the UK are about 50% higher at the end of summer than at the end of winter.1

Vitamin D deficiency (VDD) has increased profoundly in the last two decades. According to data from the National Health and Nutrition Examination Survey (NHANES), 45% of the US population had serum vitamin D levels of 30 ng/mL (considered adequate for health2) in 1998–1994, whereas in 2001–2004, this figure was only 23%, a drop of 49%.3 Concomitantly, the incidence of erectile dysfunction (ED) is rising: worldwide, the number of men with ED will increase from 150 million in 1995 to an estimated 322 million in 2025.4 ED is also prevalent in the US, affecting approximately 18–30 million men older than 20 y.5,6 Much of the worldwide upsurge may be due to an aging population, a deteriorating diet, lack of exercise and other unhealthful practices.

One recent study found risk of ED associated with “body mass index (BMI), irritative lower urinary tract symptoms, diabetes mellitus, chronic obstructive pulmonary disease (COPD) and sexual inactivity.”7

“Most cases [of ED] have a multifactorial origin and it is admitted the influence on its pathogenesis of systemic diseases, different kind of drugs, psychogenic factors, cardiovascular, endocrinological and neurological diseases. Neurologic causes of erectile dysfunction may have their origins in the central or peripheral nervous system. Among possible process of neurogenic erectile dysfunction of central origin would be tumors, cerebral vascular accidents, encephalitis, Parkinson disease, multiple sclerosis and other demyelinization diseases, dementias, olivopontocerebellar degeneration and epilepsy.”8

It has been estimated that about half of ED is related to vascular causes.9 VDD also contributes to ED apart from its negative influence on classic CVD risk factors.

The Role of Vascular Disorders in ED

ED is an inability to produce an erection sufficiently rigid for sexual intercourse. ED incidence increases with age; the most severe form (defined as never being able to achieve an erection) occurs in 2% of men aged 20–39 y, increasing to 47% of men aged 75 y.10

The penis is a highly vascularized organ, and erections are primarily vascular events.11 Sexual stimulation causes the release of neurotransmitters from the corpus cavernosa (the two cylindrical chambers that run the length of the penis) and a relaxing factor, now established as nitric oxide (NO), from the endothelial cells of the penis.12 NO is particularly important; vasodilation is essential to erection, and NO is the trigger for vasodilation in the vascular endothelium.13,14 The neurotransmitters, together with NO, cause the corpus cavernosa to relax and allow blood to flow into the penis, causing the penis to expand and sustain an erection until the process is reversed.15 Any disorder causing endothelial dysfunction (END) will also interfere with vasodilation, which prevents erection. END is an early marker for the development of atherosclerosis.16 In fact, END is the key factor in the pathophysiology of ED, and men with penile END also have END in other blood vessels.17

The increase in the number of patients with CVD risk factors parallels the worldwide increase in ED prevalence,18 which one would expect given that the two disorders result from intertwined disease processes.19 Although nonvascular factors such as depression, fatigue, stress, Parkinson disease, multiple sclerosis (MS), and hypertensive medications may affect ED,12 it is primarily a vasculogenic disease. Its most prevalent cause is the arterial occlusion of atherosclerosis, which also affects the coronary arteries and can lead to heart attack11 or, in other parts of the body, vascular events such as stroke20 and peripheral arterial disease (PAD).21

Because the penile arteries are smaller than arteries supplying other areas of the body, the first symptoms of atherosclerosis may manifest as ED, making ED one of the best predictors of CVD.13,2225 Coronary artery disease is a CVD that is highly predictable by the presence of ED. Jackson and colleagues have stated that after the onset of ED, many men experience CVD symptoms in 2–3 y and then suffer cardiovascular events (such as heart attack or stroke) in 3–5 y.26 One CVD, PAD, is also associated with the presence of ED. ED is an independent predictor of PAD, and increasing severity of ED is associated with increasing prevalence of PAD.27

Bohm and colleagues, after conducting a 2 y, randomized, controlled trial to determine whether ED was a harbinger of CVD events, demonstrated that ED was a potent predictor of myocardial infarction, stroke, and heart failure in men with preexisting CVD. ED also predicted an increased hazard ratio of 1.84 (95% CI, 1.21–2.81; p = 0.005) for all-cause death.28 In discussing the results of this study and the danger that ED drugs (phosphodiesterase-5 inhibitors) might pose by causing ED patients to ignore the presence of CVD, Bohm observed the following: “The drug works and the patient doesn’t show up anymore. These men are being treated for ED, but not the underlying cardiovascular disease. A whole segment of men is being placed at risk.”29 Other researchers have concluded that the presence of ED should trigger an aggressive assessment for occult vascular disease.11

Because both CVD and ED are, at least in part, vascular diseases, and ED is a potent predictor of CVD, the presence of risk factors for CVD also predicts the presence of ED,30 and treatments that improve CVD often also do so for ED. Treatments with lifestyle changes, for example, are quite effective. Gupta and colleagues performed a meta-analysis of randomized, controlled clinical trials and demonstrated that with lifestyle modification and CVD risk-factor reduction programs in men with ED, sexual function increased by 2.4 times with lifestyle changes alone and by 2.66 times when statin therapy was included.31 One effect of some statins is an increase in serum 25(OH)D concentrations32

One effective lifestyle change included a diet rich in whole grains, fruits, vegetables, legumes, walnuts, and olive oil; another was an exercise program (running or vigorous outdoor activity). Optimizing vitamin D levels through sunlight exposure or supplementation was not part of the lifestyle changes, but it should have been: VDD is associated with arterial stiffness and vascular dysfunction.33,34 Vasculogenic ED results from impaired smooth-muscle relaxation (endothelial-dependent or -independent), occlusion of the cavernosal arteries by atherosclerosis, or both.17

The Role of Vitamin D and Sunlight on CVD

VDD is rampant among heart disease patients; University of Kansas researchers found that 70.3% of their heart disease patients had serum vitamin D levels below 30 ng/mL (the measure considered adequate for health) and that supplemental vitamin D was associated with a 61% reduction in the risk of death.35 Giovannucci and colleagues showed that men with the lowest levels of serum vitamin D had a 2.4-times-increased risk of heart attack.36

Possible Influence of Sunlight or Vitamin D on Four Major Risk Factors for CVD and ED

We hypothesize that optimizing vitamin D levels in men with ED could achieve similar positive influences on that disease. We first discuss four classic risk factors for CVD and ED and present research suggesting the influence of sunlight or vitamin D on each factor. We then briefly discuss other influences of vitamin D on ED that have not been thoroughly covered in conjunction with the four common risk factors discussed.

Arterial calcification

Arterial calcification is a common feature of atherosclerosis, occurring in more than 90% of angiographically significant lesions.37 Measures of arterial calcification have been used since 1964 to predict myocardial infarct,38 and in 1990, 83–90% of CVD patients showed calcification of their coronary arteries—a far higher percentage than disease-free people.39 Arterial calcification remains a strong marker of increased risk of CVD,40,41 independent of other known risk factors.42,43

Arterial calcification is also a risk factor for ED. Lee and colleagues demonstrated that men who had ED were about 40% more likely to have measurable coronary artery calcification than those without ED.44 They concluded that ED “is significantly associated with abnormal coronary artery calcification and, like PAD, might warrant consideration as a coronary artery disease risk equivalent.”

Serum vitamin D levels and arterial calcification have a strong inverse relationship,37 provided that vitamin D levels are not excessively high, which can exacerbate calcification. Zittermann and colleagues explain that vitamin D exerts a biphasic dose–response curve on vascular calcification with deleterious consequences not only for vitamin D excess but also for VDD. They also note, however, that vitamin D excess seldom occurs in the general population.45 These researchers also mention that in rats, low levels of activated vitamin D (1,25-dihydroxyvitamin D or calcitriol) are associated with massive calcification of blood vessels and other soft tissues.

We hypothesize that optimizing vitamin D levels through sunlight exposure or supplementation would have positive benefits for those suffering from ED associated with vascular calcification.

Diabetes mellitus

Diabetes mellitus (DM) is a disorder of carbohydrate metabolism characterized by excessive glucose levels in urine due either to inadequate production of insulin (insulin-dependent, or type-1 DM) or to poor insulin utilization (adult-onset, or type-2 DM), both of which result in increased urine flow. Ninety percent to 95% of diabetes cases in the US are type-2.46 The presence of DM is a profound predictor of CVD, correlating to an increased risk of CVD of approximately 2.5 times.47 Although incidence of CVD has decreased somewhat in the past few decades, it has done so only in those without DM. The incidence of DM rapidly increased from 1970 to 2000,48 especially during the 1990s, and those with DM have shown a dramatic upsurge in the risk of CVD. For example, during the 1990s, the risk of acute myocardial infarction increased among those with DM by 51%, and general CVD rates in men with DM increased by 61%.49 Diabetes leads to CVD by causing END, a precursor to atherosclerosis, as follows:50 High levels of glucose in the blood inhibit the production of NO.51 This inhibition impairs vasodilation of vessels and leads to atherosclerosis52 by promoting vasoconstriction, hypertension, vascular smooth-muscle growth, inflammation, expression of cellular adhesion molecules (CAMs), platelet activation, decreased fibrinolysis and thrombosis.53 Both type-1 and type-2 DM follow this pattern. Awad and colleagues stated that “the diabetes control and complications trial clearly showed that better long-term control of blood glucose in diabetes type-1 is associated with decreased frequency and delayed the onset of microvascular complications.”54 These changes in the vessel walls affect the brain as well as the heart: diabetics younger than 55 y have 11.6 times the risk of stroke.55

DM also is associated closely with the risk of ED, as one would expect given how DM damages the vascular system. Reviewing the literature, Phe and Roupret concluded that “the pathophysiology is multifactorial, involving END, specific complications of diabetes and psychological factors.”56 In fact, compared with nondiabetic men, men with DM have three to four times the risk of ED,57,58 and the likelihood of ED in diabetic men ranges from 35–90%.59 ED in men with diabetes also occurs 10–15 y earlier.60

Sunlight exposure relates to DM. One paper showed that blood sugar levels are lower during summer than in winter,61 and another showed that exposure to UVB light increases insulin secretion.62

Vitamin D research indicates a close association between vitamin D and DM. Pittas and colleagues reported on research conducted on adults with impaired sugar tolerance and insulin resistance (both risk factors for diabetes). For 3 y, half received a placebo and the other half received vitamin D plus calcium. The rise in blood sugar levels was 15 times higher in the placebo group, and their increase in insulin resistance was 18 times higher.63 Moreover, a 4-week program of high-dose vitamin D supplementation (10,000 IU daily) in subjects with impaired fasting glucose was associated with an improved insulin sensitivity and a decreased acute insulin response to glucose, both risk factors for DM.64 Finally, a 16-week randomized, placebo-controlled study demonstrated that subjects who took 2,000 IU of vitamin D3 daily had increased β-cell function, as shown by a 37% improvement in insulin secretion.65

We hypothesize that vitamin D optimization through sunlight exposure and/or vitamin D3 supplementation would decrease END and subsequent vascular damage caused by diabetes and would reduce the risk of ED.

Hypertension and stroke

High blood pressure, or hypertension, especially systolic pressure, is a vascular disorder that is a potent predictor of CVD,66 and a strong, linear, and independent relationship exists between the two.67 Hypertension is also one of the most important risk factors for stroke.68,69 Hypertension leads to END, which is mediated by impaired NO availability after oxidative stress.16

Hypertension is also a risk factor for ED,70 which afflicts to some degree 68% of men with hypertension.71,72 Because hypertension leads to vascular damage and END, one would expect this outcome. The hypertension–ED–stroke connection is clear in the fact that over a 5-y period, men with ED have a 29% higher risk of stroke than those without ED.73

The control of renin and angiotensin also affects hypertension. Renin is an enzyme that profoundly raises blood pressure by activating the peptide angiotensin, a vasoconstrictor.74 Vitamin D may suppress hypertension by modulating the renin-angiotensin system,75,76 a regulatory cascade essential in regulating blood pressure.77 Vitamin D is a potent endocrine suppressor of renin biosynthesis, and VDD stimulates renin expression in normal mice.75 Also, mice lacking vitamin D receptors produce more renin and angiotensin, leading to hypertension.77

A direct relationship exists among hypertension, sunlight exposure, and stroke; the incidence of hypertension is considerably higher in winter than summer. One study of elderly hypertensive subjects showed that blood pressure levels averaged 165/90 in winter but 134/74 in the summer, and both stroke and heart attack rates doubled in winter.78 Hypertension also follows the same pattern in children.79 UVB light from sun lamps also effectively treats hypertension. In subjects who participated in three sessions per week of whole-body UVB exposure, vitamin D levels rose 162% after 6 weeks, and blood pressure dropped six points on both systolic and diastolic measurements.80

Sunlight exposure’s ability to lower blood pressure may also be due to another spectrum of UV light—UVA. Opländer and colleagues demonstrated that whole-body irradiation with UVA lowered systemic blood pressure by stimulating NO production, significantly increasing intradermal levels of NO. These increased NO levels were accompanied by increased flow-mediated vasodilation of the brachial artery.81 Such vasodilation could also enhance sexual function in men by lessening ED. Another investigation showed that men with the lowest vitamin D levels also had 6.13 times the risk of developing hypertension; women with the lowest levels had 2.67 times the risk.82 Other investigations show a close association between VDD and the likelihood of stroke.83

We hypothesize that vitamin D optimization through sunlight exposure or vitamin D3 supplementation would decrease vascular damage caused by hypertension and reduce the risk of ED.

Inflammation in the vascular endothelium

Inflammation is a reaction of damaged tissue that manifests as redness, swelling, pain, tenderness and heat. It is primarily a protective response against injury. Normal vascular endothelium has anti-inflammatory properties, but endothelial function is impaired in the presence of inflammatory conditions and increased oxidative stress.17,84 When injurious agents persist or healing is disturbed, inflammation, tissue injury and attempts at repair coexist. This combination of factors can lead to chronic inflammation, harming many body systems, including the vascular system.85 Inflammation drives the formation, progression, and rupture of atherosclerotic plaques; it is one of the stimuli that cause CAMs to further recruit inflammatory blood monocytes that adhere to the endothelium, and through chemotactic stimulus by inflammatory proteins known as chemokines and inflammatory cytokines, enter between the endothelial cells and invade the intima of the blood vessel. In the intima, they mature into macrophages, which engulf lipids and create foam cells, leading to atherosclerotic lesions.86,87 Macrophages also release growth factors that are destructive to blood vessels.88-91, Even subclinical inflammation affects endothelial function and is involved in all stages of atherosclerosis.17 Thus, the endothelium as well as the entire blood vessel is damaged, and atherosclerosis proceeds.

ED is also closely associated with inflammation. C-reactive protein (CRP), a major marker of inflammation, is significantly higher in patients with ED than in subjects without ED.92,93 Interestingly, CRP itself reduces production of NO, leading to further vascular damage.94 Also, CAMs are increased in men with ED who have not manifested cardiovascular risk factors or overt vascular damage.95 Another marker of inflammation is tumor necrosis factor α (TNFα), an inflammatory cytokine that is markedly elevated in men with ED and is another common link between ED and CVD.96

Vitamin D may promote vascular health by inhibiting inflammation.97 Vitamin D supplements and injections may lower CRP levels as much as 40%98 and improve cytokine profiles; it inhibits the production of proinflammatory cytokines99,100 while stimulating the production of anti-inflammatory cytokines.100,101 One pro-inflammatory cytokine, TNFα, is inversely related to regular exposure to sunlight and artificial sources of UVB among women,102 and the same is probably true for men. Two CAMs induced by TNFα are also significantly decreased after incubation with activated vitamin D.103 In addition, Oh and colleagues have shown that in patients with type 2 diabetes, active vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake,104,105 inhibiting the inflammatory atherosclerotic process described earlier.

We hypothesize that vitamin D optimization through sunlight exposure or vitamin D3 supplementation would decrease vascular damage caused by inflammation and reduce the risk of ED. We searched for evidence contradicting our hypothesis regarding VDD and ED but found none.

Other influences of vitamin D on ED

Endothelial-progenitor cells

Endothelial progenitor cells (EPCs) are necessary for maintaining the health of the arterial endothelium. VDD is associated with depletion of EPCs and consequent END in patients with type 2 DM.106 This research also showed that VDD was associated with reduced vasodilation as measured by brachial artery flow–mediated dilation.

NO synthases

NO synthases (NOS) are a family of enzymes that catalyze the production of NO from l-arginine. Activated vitamin D stimulates the production of substantial quantities of NOS and NO in macrophages produced in response to tuberculosis,107 in bone108 and in endothelial cells,109 the last being vital to vascular dilation and thereby important to inhibiting ED. This behavior may explain why endothelium-derived, NO-evoked dilation is halved in arteries from vitamin D–deficient male rats.110


PAD is a CVD that is closely associated with the presence of ED. Chua and colleagues have shown that VDD could be an easily correctable independent risk factor for PAD.111

Platelet activation

Platelet activation by proinflammatory factors is another aspect of END. In experiments, vitamin D attenuates platelet activation while reducing the expression of two CAMs, VCAM-1 and MT1-MMP.112 Researchers in Israel also identified 50 patients who had a heart attack or an episode of unstable angina, placing half of them on a regimen of 4,000 IU of vitamin D daily for 5 d. The vitamin D group showed a decrease in VCAM-1 as well as another inflammation marker, interleukin 6. The patients who did not receive vitamin D showed clear increases in both inflammation markers.113 The researchers stated, “VCAM-1 is central to atherosclerotic plaque formation and [interleukin 6] is broadly associated with coronary risk.” Both studies indicate that vitamin D has actions that reduce END and thereby have a positive influence on ED.

Vascular smooth-muscle cell proliferation

Vascular smooth-muscle cell (VSMC) proliferation is part of the process of atherosclerosis. Vitamin D has an antiproliferative influence on VSMC,114,115 which indicates antiatherosclerotic properties that may positively influence ED.


Vasodilation is vital to achieving erection. VDD is inversely associated with flow-mediated vasodilation, END, and arterial stiffness irrespective of the traditional risk factors for CVD and ED33 discussed here. Therefore, VDD—in addition to exacerbating the classical risk factors for CVD—may directly lead to ED.

Nonvascular conditions comorbid with ED and influenced by vitamin D

We have thus far discussed the relationship of ED to CVD and considered the influence of vitamin D levels or treatment on both disorders. Evidence in addition to that presented in this review in support of the hypothesis that VDD contributes to ED risk was sought by searching for papers linking ED to sun exposure, race, and disorders linked to VDD, and whether animal models regarding vitamin D and ED had been conducted. No evidence linking ED to sun exposure was found. No animal model studies of ED and vitamin D were found. In a cross-sectional study in the United States in 2000 and 2001, the estimated prevalence of ED was “21.9% (95% CI, 18.8–24.9) in whites, 24.4% (95% CI, 18.4–30.5) in blacks, and 19.9% (95% CI, 13.9–25.9) in Hispanics.”116 Another paper reported that Black and Hispanic men in the Boston area had 25% higher rate of ED, but attributed the finding to socioeconomic status rather than race117

Several other nonvascular diseases and conditions are closely associated with both ED and VDD, strengthening the hypothesis that VDD contributes to ED and offering another avenue whereby vitamin D optimization might mitigate or reverse it. Those diseases and conditions include Alzheimer,118,119 asthma,120,121 chronic kidney disease,122-124 depression,125,126 falls and fractures,127,128 metabolic syndrome,129,130 MS,131-134 obesity,135,136 Parkinson,137,138 periodontal disease,139,140 psoriasis141,142 and smoking.143,144Table 1 summarizes research regarding those diseases and conditions. For all of these diseases, VDD appears to be an important risk factor. Thus, avoiding VDD earlier in life may reduce the risk of ED. In addition, for some of the diseases such as atopic dermatitis145,146 and multiple sclerosis, increasing vitamin D intake or production can reduce the symptoms and may also reduce the risk of ED.

Table thumbnail
Table 1. Evidence for influences of vitamin D on nonvascular diseases and conditions associated with ED


The research presented suggests that many common mechanisms underlie both CVD and ED, and that VDD is closely associated with both disorders. We hypothesize that optimizing serum vitamin D levels through sunlight exposure or vitamin D supplementation helps delay the onset of ED. Coupled with positive changes in lifestyle, such optimization may restore normal sexual function to some men. This hypothesis should be tested through observational and intervention studies. If proven by further research, such therapy would offer an alternative or complement to phosphodiesterase-5 inhibitors, which, though exceptionally effective and a first choice for treatment, have been associated with many negative side effects,147 and which, because of their efficacy in producing erections, may cause men with ED to ignore the possibility they might have occult underlying CVD.



cellular adhesion molecules
95% CI
95% confidence interval
C-reactive protein
cardiovascular disease
diabetes mellitus
erectile dysfunction
endothelial dysfunction
nitric oxide
nitric oxide synthases
peripheral arterial disease
vitamin D deficiency


1. Pilz S, Tomaschitz A, März W, Drechsler C, Ritz E, Zittermann A, et al. Vitamin D, cardiovascular disease and mortality. Clin Endocrinol (Oxf) 2011;75:575–84. doi: 10.1111/j.1365-2265.2011.04147.x. [PubMed] [Cross Ref]
2. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev. 2010;9:709–15. doi: 10.1016/j.autrev.2010.06.009. [PubMed] [Cross Ref]
3. Ginde AA, Liu MC, Camargo CA., Jr Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169:626–32. doi: 10.1001/archinternmed.2008.604. [PMC free article] [PubMed] [Cross Ref]
4. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50–6. doi: 10.1046/j.1464-410x.1999.00142.x. [PubMed] [Cross Ref]
5. Araujo AB, Hall SA, Ganz P, Chiu GR, Rosen RC, Kupelian V, et al. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score? J Am Coll Cardiol. 2010;55:350–6. doi: 10.1016/j.jacc.2009.08.058. [PMC free article] [PubMed] [Cross Ref]
6. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res. 2000;12(Suppl 4):S6–11. doi: 10.1038/sj.ijir.3900567. [PubMed] [Cross Ref]
7. Schouten BW, Bohnen AM, Dohle GR, Groeneveld FP, Willemsen S, Thomas S, et al. Risk factors for deterioration of erectile function: the Krimpen study. Int J Androl. 2009;32:166–75. doi: 10.1111/j.1365-2605.2007.00830.x. [PubMed] [Cross Ref]
8. Valles Antuña C, Ferńndez Gómez JM, Escaf S, Ferńndez-González F. Neurogenic etiology in patients with erectile dysfunction. Arch Esp Urol. 2008;61:403–11. [PubMed]
9. Kloner RA. Erectile dysfunction and cardiovascular risk factors. Urol Clin North Am. 2005;32:397–402, v. doi: 10.1016/j.ucl.2005.08.005. [PubMed] [Cross Ref]
10. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ, Urologic Diseases in America Project Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006;166:207–12. doi: 10.1001/archinte.166.2.207. [PubMed] [Cross Ref]
11. Billups KL, Bank AJ, Padma-Nathan H, Katz SD, Williams RA. Erectile dysfunction as a harbinger for increased cardiometabolic risk. Int J Impot Res. 2008;20:236–42. doi: 10.1038/sj.ijir.3901634. [PubMed] [Cross Ref]
12. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart. 2003;89:251–3. doi: 10.1136/heart.89.3.251. [PMC free article] [PubMed] [Cross Ref]
13. Meldrum DR, Gambone JC, Morris MA, Meldrum DA, Esposito K, Ignarro LJ. The link between erectile and cardiovascular health: the canary in the coal mine. Am J Cardiol. 2011;108:599–606. doi: 10.1016/j.amjcard.2011.03.093. [PubMed] [Cross Ref]
14. Bird IM. Endothelial nitric oxide synthase activation and nitric oxide function: new light through old windows. J Endocrinol. 2011;210:239–41. doi: 10.1530/JOE-11-0216. [PubMed] [Cross Ref]
15. Web MD Erectile Dysfunction Health Center. Erectile dysfunction: how an erection occurs. Accessed October 29, 2011.
16. Ghiadoni L, Taddei S, Virdis A. Hypertension and endothelial dysfunction: therapeutic approach. Curr Vasc Pharmacol. 2012;10:42–60. doi: 10.2174/157016112798829823. [PubMed] [Cross Ref]
17. Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol. 2007;52:1590–600. doi: 10.1016/j.eururo.2007.08.004. [PubMed] [Cross Ref]
18. Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc. 2009;84:139–48. doi: 10.4065/84.2.139. [PMC free article] [PubMed] [Cross Ref]
19. Menezes A, Artham S, Lavie CJ, Milani RV, O’Keefe J. Erectile dysfunction and cardiovascular disease. Postgrad Med. 2011;123:7–16. [PubMed]
20. Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. Circulation. 2006;114:63–75. doi: 10.1161/CIRCULATIONAHA.105.593418. [PubMed] [Cross Ref]
21. Stöppler MC, Lee D, Kulic D, Peripheral MD. Vascular Disease. Medicine Accessed January 5, 2012.
22. Erectile dysfunction. Mayo Clinic Online. Accessed October 25, 2011.
23. Gazzaruso C, Coppola A, Montalcini T, Valenti C, Garzaniti A, Pelissero G, et al. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine. 2011;40:273–9. doi: 10.1007/s12020-011-9523-9. [PubMed] [Cross Ref]
24. Salem S, Abdi S, Mehrsai A, Saboury B, Saraji A, Shokohideh V, et al. Erectile dysfunction severity as a risk predictor for coronary artery disease. J Sex Med. 2009;6:3425–32. doi: 10.1111/j.1743-6109.2009.01515.x. [PubMed] [Cross Ref]
25. Billups KL, Bank AJ, Padma-Nathan H, Katz S, Williams R. Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. J Sex Med. 2005;2:40–50, discussion 50-2. doi: 10.1111/j.1743-6109.2005.20104_1.x. [PubMed] [Cross Ref]
26. Jackson G, Boon N, Eardley I, Kirby M, Dean J, Hackett G, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract. 2010;64:848–57. doi: 10.1111/j.1742-1241.2010.02410.x. [PubMed] [Cross Ref]
27. Polonsky TS, Taillon LA, Sheth H, Min JK, Archer SL, Ward RP. The association between erectile dysfunction and peripheral arterial disease as determined by screening ankle-brachial index testing. Atherosclerosis. 2009;207:440–4. doi: 10.1016/j.atherosclerosis.2009.05.005. [PubMed] [Cross Ref]
28. Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, et al. ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation. 2010;121:1439–46. doi: 10.1161/CIRCULATIONAHA.109.864199. [PubMed] [Cross Ref]
29. Los Angeles Times Online. March 16, 2010. Mar16 Accessed October 26, 2011.
30. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol. 2004;43:1405–11. doi: 10.1016/j.jacc.2003.11.041. [PubMed] [Cross Ref]
31. Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011;171:1797–803. doi: 10.1001/archinternmed.2011.440. [PubMed] [Cross Ref]
32. Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M. Effect of Rosuvastatin Monotherapy and in Combination With Fenofibrate or Omega-3 Fatty Acids on Serum Vitamin D Levels. J Cardiovasc Pharmacol Ther. 2012 doi: 10.1177/1074248412439470. In press. [PubMed] [Cross Ref]
33. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L, et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol. 2011;58:186–92. doi: 10.1016/j.jacc.2011.02.051. [PubMed] [Cross Ref]
34. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011;57:63–9. doi: 10.1161/HYPERTENSIONAHA.110.160929. [PMC free article] [PubMed] [Cross Ref]
35. Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol. 2012;109:359–63. doi: 10.1016/j.amjcard.2011.09.020. [PubMed] [Cross Ref]
36. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxy-vitamin D and risk of myocardial infarction in men. Ann Intern Med. 2008;168:1174–80. doi: 10.1001/archinte.168.11.1174. [PubMed] [Cross Ref]
37. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755–60. [PubMed]
38. Beadenkopf WG, Daoud AS, Love BM. Calcification in the coronary arteries and its relationship to arteriosclerosis and myocardial infarction. Am J Roentgenol Radium Ther Nucl Med. 1964;92:865–71. [PubMed]
39. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–32. doi: 10.1016/0735-1097(90)90282-T. [PubMed] [Cross Ref]
40. Feldman C, Vitola D, Schiavo N. Detection of coronary artery disease based on the calcification index obtained by helical computed tomography. Arq Bras Cardiol. 2000;75:471–80. doi: 10.1590/S0066-782X2000001200002. [PubMed] [Cross Ref]
41. Kitamura A, Kobayashi T, Ueda K, Okada T, Awata N, Sato S, et al. Evaluation of coronary artery calcification by multi-detector row computed tomography for the detection of coronary artery stenosis in Japanese patients. J Epidemiol. 2005;15:187–93. doi: 10.2188/jea.15.187. [PubMed] [Cross Ref]
42. Santos RD, Rumberger JA, Budoff MJ, Shaw LJ, Orakzai SH, Berman D, et al. Thoracic aorta calcification detected by electron beam tomography predicts all-cause mortality. Atherosclerosis. 2010;209:131–5. [PubMed]
43. Jacobs PC, Prokop M, van der Graaf Y, Gondrie MJ, Janssen KJ, de Koning HJ, et al. Comparing coronary artery calcium and thoracic aorta calcium for prediction of all-cause mortality and cardiovascular events on low-dose non-gated computed tomography in a high-risk population of heavy smokers. Atherosclerosis. 2010;209:455–62. doi: 10.1016/j.atherosclerosis.2009.09.031. [PubMed] [Cross Ref]
44. Lee JH, Ngengwe R, Jones P, Tang F, O’Keefe JH. Erectile dysfunction as a coronary artery disease risk equivalent. J Nucl Cardiol. 2008;15:800–3. [PubMed]
45. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol. 2007;18:41–6. doi: 10.1097/MOL.0b013e328011c6fc. [PubMed] [Cross Ref]
46. National Diabetes Fact Sheet. 2007. Available at Accessed November 25, 2011.
47. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167:1145–51. doi: 10.1001/archinte.167.11.1145. [PubMed] [Cross Ref]
48. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB., Sr. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation. 2006;113:2914–8. doi: 10.1161/CIRCULATIONAHA.106.613828. [PubMed] [Cross Ref]
49. Fang J, Alderman MH. Impact of the increasing burden of diabetes on acute myocardial infarction in New York City: 1990-2000. Diabetes. 2006;55:768–73. doi: 10.2337/diabetes.55.03.06.db05-1196. [PubMed] [Cross Ref]
50. Tousoulis D, Kampoli AM, Stefanadis C. Diabetes mellitus and vascular endothelial dysfunction: current perspectives. Curr Vasc Pharmacol. 2012;10:19–32. doi: 10.2174/157016112798829797. [PubMed] [Cross Ref]
51. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963–74. doi: 10.1038/sj.bjp.0703393. [PMC free article] [PubMed] [Cross Ref]
52. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567–74. doi: 10.1016/0735-1097(95)00522-6. [PubMed] [Cross Ref]
53. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81. doi: 10.1001/jama.287.19.2570. [PubMed] [Cross Ref]
54. Awad H, Salem A, Gadalla A, El Wafa NA, Mohamed OA. Erectile function in men with diabetes type 2: correlation with glycemic control. Int J Impot Res. 2010;22:36–9. doi: 10.1038/ijir.2009.39. [PubMed] [Cross Ref]
55. You RX, McNeil JJ, O’Malley HM, Davis SM, Thrift AG, Donnan GA. Risk factors for stroke due to cerebral infarction in young adults. Stroke. 1997;28:1913–8. doi: 10.1161/01.STR.28.10.1913. [PubMed] [Cross Ref]
56. Phé V, Rouprêt M. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. Diabetes Metab. 2012;38:1–13. doi: 10.1016/j.diabet.2011.09.003. [PubMed] [Cross Ref]
57. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151–7. doi: 10.1016/j.amjmed.2006.06.010. [PubMed] [Cross Ref]
58. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol. 2001;166:569–74, discussion 574-5. doi: 10.1016/S0022-5347(05)65986-1. [PubMed] [Cross Ref]
59. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6:1232–47. doi: 10.1111/j.1743-6109.2008.01168.x. [PubMed] [Cross Ref]
60. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61. [PubMed]
61. Ishii H, Suzuki H, Baba T, Nakamura K, Watanabe T. Seasonal variation of glycemic control in type 2 diabetic patients. Diabetes Care. 2001;24:1503. doi: 10.2337/diacare.24.8.1503. [PubMed] [Cross Ref]
62. Colas C, Garabedian M, Fontbonne A, Guillozo H, Slama G, Desplanque N, et al. Insulin secretion and plasma 1,25-(OH)2D after UV-B irradiation in healthy adults. Horm Metab Res. 1989;21:154–5. doi: 10.1055/s-2007-1009178. [PubMed] [Cross Ref]
63. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30:980–6. doi: 10.2337/dc06-1994. [PubMed] [Cross Ref]
64. Nazarian S, St Peter JV, Boston RC, Jones SA, Mariash CN. Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl Res. 2011;158:276–81. doi: 10.1016/j.trsl.2011.05.002. [PMC free article] [PubMed] [Cross Ref]
65. Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011;94:486–94. doi: 10.3945/ajcn.111.011684. [PubMed] [Cross Ref]
66. Bowman TS, Sesso HD, Gaziano JM. Effect of age on blood pressure parameters and risk of cardiovascular death in men. Am J Hypertens. 2006;19:47–52. doi: 10.1016/j.amjhyper.2005.06.024. [PubMed] [Cross Ref]
67. Gu D, Kelly TN, Wu X, Chen J, Duan X, Huang JF, et al. Blood pressure and risk of cardiovascular disease in Chinese men and women. Am J Hypertens. 2008;21:265–72. doi: 10.1038/ajh.2007.59. [PubMed] [Cross Ref]
68. Sanford School of Medicine, Stanford Stroke Center. Available online at Accessed Nov 30, 2011.
69. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM. Risk factors. Stroke. 1997;38:1507–17. [PubMed]
70. Manolis A, Doumas M. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens. 2008;26:2074–84. doi: 10.1097/HJH.0b013e32830dd0c6. [PubMed] [Cross Ref]
71. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A, et al. Hypertension is associated with severe erectile dysfunction. J Urol. 2000;164:1188–91. doi: 10.1016/S0022-5347(05)67138-8. [PubMed] [Cross Ref]
72. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology. 2004;64:1196–201. doi: 10.1016/j.urology.2004.08.059. [PubMed] [Cross Ref]
73. Chung SD, Chen YK, Lin HC, Lin HC. Increased risk of stroke among men with erectile dysfunction: a nationwide population-based study. J Sex Med. 2011;8:240–6. doi: 10.1111/j.1743-6109.2010.01973.x. [PubMed] [Cross Ref]
74. Sigmund CD. Regulation of renin expression and blood pressure by vitamin D(3) J Clin Invest. 2002;110:155–6. [PMC free article] [PubMed]
75. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89-90:387–92. doi: 10.1016/j.jsbmb.2004.03.004. [PubMed] [Cross Ref]
76. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension. 2010;55:1283–8. doi: 10.1161/HYPERTENSIONAHA.109.148619. [PMC free article] [PubMed] [Cross Ref]
77. Ullah MI, Uwaifo GI, Nicholas WC, Koch CA. Does vitamin d deficiency cause hypertension? Current evidence from clinical studies and potential mechanisms. Int J Endocrinol. 2010;2010:579640. [PMC free article] [PubMed]
78. Charach G, Rabinovich PD, Weintraub M. Seasonal changes in blood pressure and frequency of related complications in elderly Israeli patients with essential hypertension. Gerontology. 2004;50:315–21. doi: 10.1159/000079130. [PubMed] [Cross Ref]
79. Polat M, Akil I, Yuksel H, Coskun S, Yilmaz D, Erguder I, et al. The effect of seasonal changes on blood pressure and urine specific gravity in children living in Mediterranean climate. Med Sci Monit. 2006;12:CR186–90. [PubMed]
80. Krause R, Bühring M, Hopfenmüller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet. 1998;352:709–10. doi: 10.1016/S0140-6736(05)60827-6. [PubMed] [Cross Ref]
81. Opländer C, Volkmar CM, Paunel-Görgülü A, van Faassen EE, Heiss C, Kelm M, et al. Whole body UVA irradiation lowers systemic blood pressure by release of nitric oxide from intracutaneous photolabile nitric oxide derivates. Circ Res. 2009;105:1031–40. doi: 10.1161/CIRCRESAHA.109.207019. [PubMed] [Cross Ref]
82. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49:1063–9. doi: 10.1161/HYPERTENSIONAHA.107.087288. [PubMed] [Cross Ref]
83. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, et al. Intermountain Heart Collaborative (IHC) Study Group Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106:963–8. doi: 10.1016/j.amjcard.2010.05.027. [PubMed] [Cross Ref]
84. Trepels T, Zeiher AM, Fichtlscherer S. The endothelium and inflammation. Endothelium. 2006;13:423–9. doi: 10.1080/10623320601061862. [PubMed] [Cross Ref]
85. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J. 2011;75:2739–48. doi: 10.1253/circj.CJ-11-1184. [PubMed] [Cross Ref]
86. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74:213–20. doi: 10.1253/circj.CJ-09-0706. [PubMed] [Cross Ref]
87. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S–60S. [PubMed]
88. Cybulsky MI, Gimbrone MA., Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788–91. doi: 10.1126/science.1990440. [PubMed] [Cross Ref]
89. Li H, Cybulsky MI, Gimbrone MA, Jr., Libby P. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol. 1993;143:1551–9. [PubMed]
90. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275–81. doi: 10.1016/S1097-2765(00)80139-2. [PubMed] [Cross Ref]
91. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894–7. doi: 10.1038/29788. [PubMed] [Cross Ref]
92. Chiurlia E, D’Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol. 2005;46:1503–6. doi: 10.1016/j.jacc.2005.06.068. [PubMed] [Cross Ref]
93. Zambon JP, Mendonça RR, Wroclawski ML, Karam Junior A, Santos RD, Carvalho JA, et al. Cardiovascular and metabolic syndrome risk among men with and without erectile dysfunction: case-control study. Sao Paulo Med J. 2010;128:137–40. doi: 10.1590/S1516-31802010000300006. [PubMed] [Cross Ref]
94. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913–9. doi: 10.1161/01.CIR.0000029802.88087.5E. [PubMed] [Cross Ref]
95. Bocchio M, Desideri G, Scarpelli P, Necozione S, Properzi G, Spartera C, et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol. 2004;171:1601–4. doi: 10.1097/01.ju.0000116325.06572.85. [PubMed] [Cross Ref]
96. Carneiro FS, Webb RC, Tostes RC. Emerging role for TNF-α in erectile dysfunction. J Sex Med. 2010;7:3823–34. doi: 10.1111/j.1743-6109.2010.01762.x. [PMC free article] [PubMed] [Cross Ref]
97. Guillot X, Semerano L, Saidenberg-Kermanac’h N, Falgarone G, Boissier MC. Vitamin D and inflammation. Joint Bone Spine. 2010;77:552–7. doi: 10.1016/j.jbspin.2010.09.018. [PubMed] [Cross Ref]
98. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr. 2005;94:483–92. doi: 10.1079/BJN20051544. [PubMed] [Cross Ref]
99. Müller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine. 1992;4:506–12. doi: 10.1016/1043-4666(92)90012-G. [PubMed] [Cross Ref]
100. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:731–2. [PubMed]
101. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol. 2001;145:351–7. doi: 10.1530/eje.0.1450351. [PubMed] [Cross Ref]
102. Peterson CA, Heffernan ME. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm (Lond) 2008;5:10. doi: 10.1186/1476-9255-5-10. [PMC free article] [PubMed] [Cross Ref]
103. Martinesi M, Bruni S, Stio M, Treves C. 1,25-Dihydroxyvitamin D3 inhibits tumor necrosis factor-alpha-induced adhesion molecule expression in endothelial cells. Cell Biol Int. 2006;30:365–75. doi: 10.1016/j.cellbi.2006.01.004. [PubMed] [Cross Ref]
104. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, et al. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation. 2009;120:687–98. doi: 10.1161/CIRCULATIONAHA.109.856070. [PMC free article] [PubMed] [Cross Ref]
105. Riek AE, Oh J, Bernal-Mizrachi C. Vitamin D regulates macrophage cholesterol metabolism in diabetes. J Steroid Biochem Mol Biol. 2010;121:430–3. doi: 10.1016/j.jsbmb.2010.03.018. [PubMed] [Cross Ref]
106. Yiu YF, Chan YH, Yiu KH, Siu CW, Li SW, Wong LY, et al. Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:E830–5. doi: 10.1210/jc.2010-2212. [PubMed] [Cross Ref]
107. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, Kwiatkowski D. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun. 1998;66:5314–21. [PMC free article] [PubMed]
108. Willems HM, van den Heuvel EG, Carmeliet G, Schaafsma A, Klein-Nulend J, Bakker AD. VDR dependent and independent effects of 1,25-dihydroxyvitamin D3 on nitric oxide production by osteoblasts. Steroids. 2012;77:126–31. doi: 10.1016/j.steroids.2011.10.015. [PubMed] [Cross Ref]
109. Molinari C, Uberti F, Grossini E, Vacca G, Carda S, Invernizzi M, et al. 1α,25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. Cell Physiol Biochem. 2011;27:661–8. doi: 10.1159/000330075. [PubMed] [Cross Ref]
110. Tare M, Emmett SJ, Coleman HA, Skordilis C, Eyles DW, Morley R, et al. Vitamin D insufficiency is associated with impaired vascular endothelial and smooth muscle function and hypertension in young rats. J Physiol. 2011;589:4777–86. doi: 10.1113/jphysiol.2011.214726. [PubMed] [Cross Ref]
111. Chua GT, Chan YC, Cheng SW. Vitamin D status and peripheral arterial disease: evidence so far. Vasc Health Risk Manag. 2011;7:671–5. [PMC free article] [PubMed]
112. Stach K, Kälsch AI, Nguyen XD, Elmas E, Kralev S, Lang S, et al. 1α,25-dihydroxyvitamin D3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial cells. Cardiology. 2011;118:107–15. doi: 10.1159/000327547. [PubMed] [Cross Ref]
113. Nathan Seppa, Science News December 17, 2011, reporting on AHA Scientific sessions: Arnson Y, Amital H, Mosseri M. Short-term vitamin D inhibits the increase in inflammatory cytokine and adhesion molecule levels in patients after a coronary event. Abstract # 11373. American Heart Association Scientific Sessions, November 12, 2011, Orlando, Fla.
114. Chen S, Law CS, Gardner DG. Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of cdk2 activity. J Steroid Biochem Mol Biol. 2010;122:326–32. doi: 10.1016/j.jsbmb.2010.08.007. [PubMed] [Cross Ref]
115. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, et al. 25-hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005;111:1666–71. doi: 10.1161/01.CIR.0000160353.27927.70. [PubMed] [Cross Ref]
116. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 2007;4:57–65. doi: 10.1111/j.1743-6109.2006.00340.x. [PubMed] [Cross Ref]
117. Kupelian V, Link CL, Rosen RC, McKinlay JB. Socioeconomic status, not race/ethnicity, contributes to variation in the prevalence of erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. J Sex Med. 2008;5:1325–33. doi: 10.1111/j.1743-6109.2008.00822.x. [PubMed] [Cross Ref]
118. Zeiss AM, Davies HD, Wood M, Tinklenberg JR. The incidence and correlates of erectile problems in patients with Alzheimer’s disease. Arch Sex Behav. 1990;19:325–31. doi: 10.1007/BF01541927. [PubMed] [Cross Ref]
119. Grant WB. Does vitamin D reduce the risk of dementia? J Alzheimers Dis. 2009;17:151–9. [PubMed]
120. Chou KT, Huang CC, Chen YM, Perng DW, Chao HS, Chan WL, et al. Asthma and risk of erectile dysfunction--a nationwide population-based study. J Sex Med. 2011;8:1754–60. doi: 10.1111/j.1743-6109.2011.02242.x. [PubMed] [Cross Ref]
121. Bozzetto S, Carraro S, Giordano G, Boner A, Baraldi E. Asthma, allergy and respiratory infections: the vitamin D hypothesis. Allergy. 2012;67:10–7. doi: 10.1111/j.1398-9995.2011.02711.x. [PubMed] [Cross Ref]
122. Malekmakan L, Shakeri S, Haghpanah S, Pakfetrat M, Sarvestani AS, Malekmakan A. Epidemiology of erectile dysfunction in hemodialysis patients using IIEF questionnaire. Saudi J Kidney Dis Transpl. 2011;22:232–6. [PubMed]
123. Kim HS, Chung W, Kim S. Vitamin d, and kidney disease. Electrolyte Blood Press. 2011;9:1–6. doi: 10.5049/EBP.2011.9.1.1. [PMC free article] [PubMed] [Cross Ref]
124. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011;58:374–82. [PubMed]
125. Perelman MA. Erectile dysfunction and depression: screening and treatment. Urol Clin North Am. 2011;38:125–39. doi: 10.1016/j.ucl.2011.03.004. [PubMed] [Cross Ref]
126. Hoang MT, Defina LF, Willis BL, Leonard DS, Weiner MF, Brown ES. Association between low serum 25-hydroxyvitamin D and depression in a large sample of healthy adults: the Cooper Center longitudinal study. Mayo Clin Proc. 2011;86:1050–5. doi: 10.4065/mcp.2011.0208. [PMC free article] [PubMed] [Cross Ref]
127. Frost M, Abrahamsen B, Masud T, Brixen K. Risk factors for fracture in elderly men: a population-based prospective study. Osteoporos Int. 2012;23:521–31. doi: 10.1007/s00198-011-1575-4. [PubMed] [Cross Ref]
128. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257–64. doi: 10.1001/jama.293.18.2257. [PubMed] [Cross Ref]
129. Lee RK, Chughtai B, Te AE, Kaplan SA. Sexual function in men with metabolic syndrome. Urol Clin North Am. 2012;39:53–62. doi: 10.1016/j.ucl.2011.09.008. [PubMed] [Cross Ref]
130. Al-Daghri NM, Alkharfy KM, Al-Saleh Y, Al-Attas OS, Alokail MS, Al-Othman A, et al. Modest reversal of metabolic syndrome manifestations with vitamin D status correction: a 12-month prospective study. Metabolism. 2011 doi: 10.1016/j.metabol.2011.09.017. In press. [PubMed] [Cross Ref]
131. Severson B. Sexual Dysfunction and Multiple Sclerosis. U.S. Dept. of Veterans Affairs, Multiple Sclerosis Center of Excellence. 2010. Available at Accessed Dec 27, 2011.
132. Boston Medical Group Online. Multiple Sclerosis and Erectile dysfunction. Accessed December 27, 2011.
133. Munger KL, Zhang SM, O’Reilly E, Herńn MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60–5. [PubMed]
134. Mirzaei F, Michels KB, Munger K, O’Reilly E, Chitnis T, Forman MR, et al. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol. 2011;70:30–40. doi: 10.1002/ana.22456. [PMC free article] [PubMed] [Cross Ref]
135. Chao JK, Hwang TI, Ma MC, Kuo WH, Liu JH, Chen YP, et al. A survey of obesity and erectile dysfunction of men conscripted into the military in Taiwan. J Sex Med. 2011;8:1156–63. doi: 10.1111/j.1743-6109.2010.02181.x. [PubMed] [Cross Ref]
136. Earthman CP, Beckman LM, Masodkar K, Sibley SD. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes (Lond) 2012;36:387–96. doi: 10.1038/ijo.2011.119. [PubMed] [Cross Ref]
137. Roumiguié M, Guillotreau J, Castel-Lacanal E, Malavaud B, De Boissezon X, Marque P, et al. [Assessment of sexual function in men with idiopathic Parkinson’s disease using the International Index of Erectile Dysfunction (IIEF-15)] Prog Urol. 2011;21:67–71. [PubMed]
138. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V, Parkinson Study Group DATATOP Investigators High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol. 2011;68:314–9. doi: 10.1001/archneurol.2011.30. [PubMed] [Cross Ref]
139. Zadik Y, Bechor R, Galor S, Justo D, Heruti RJ. Erectile dysfunction might be associated with chronic periodontal disease: two ends of the cardiovascular spectrum. J Sex Med. 2009;6:1111–6. doi: 10.1111/j.1743-6109.2008.01141.x. [PubMed] [Cross Ref]
140. Grant WB, Boucher BJ. Are Hill’s criteria for causality satisfied for vitamin D and periodontal disease? Dermatoendocrinol. 2010;2:30–6. doi: 10.4161/derm.2.1.12488. [PMC free article] [PubMed] [Cross Ref]
141. Chung SD, Keller JJ, Chu TW, Lin HC. Psoriasis and the risk of erectile dysfunction: a population-based case-control study. J Sex Med. 2012;9:130–5. doi: 10.1111/j.1743-6109.2011.02510.x. [PubMed] [Cross Ref]
142. Rácz E, Prens EP, Kurek D, Kant M, de Ridder D, Mourits S, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol. 2011;131:1547–58. doi: 10.1038/jid.2011.53. [PubMed] [Cross Ref]
143. Safarinejad MR. Prevalence and risk factors for erectile dysfunction in a population-based study in Iran. Int J Impot Res. 2003;15:246–52. doi: 10.1038/sj.ijir.3901024. [PubMed] [Cross Ref]
144. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr. 1999;53:920–6. doi: 10.1038/sj.ejcn.1600870. [PubMed] [Cross Ref]
145. Chung SD, Keller JJ, Lin HC. Association of erectile dysfunction with atopic dermatitis: a population-based case-control study. J Sex Med. 2012;9:679–85. doi: 10.1111/j.1743-6109.2011.02587.x. [PubMed] [Cross Ref]
146. Amestejani M, Salehi BS, Vasigh M, Sobhkhiz A, Karami M, Alinia H, et al. Vitamin d supplementation in the treatment of atopic dermatitis: a clinical trial study. J Drugs Dermatol. 2012;11:327–30. [PubMed]
147. Viagra Side Effects Accessed Dec. 20, 2011.

Articles from Dermato-endocrinology are provided here courtesy of Landes Bioscience